Skip to main content
Erschienen in: Urolithiasis 6/2019

16.03.2019 | Original Paper

Cancer as a risk factor for urinary tract calculi: a retrospective cohort study using ‘The Health Improvement Network’

Cancer and urinary tract calculi

verfasst von: Ankush Mittal, Motaz Elmahdy Hassan, Joht Singh Chandan, Brian H. Willis, Krishnarajah Nirantharakumar, Kesvapilla Subramonian

Erschienen in: Urolithiasis | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Urolithiasis is a common condition that poses significant morbidity to patients. There are similarities in the development of certain cancers and urinary tract calculi (UTC), however, little is known about their temporal relationship. This study aims to identify if cancer is a risk factor for the development of UTC.

Methods

A population-based retrospective cohort study was conducted for the period 1st January 1990 to 1st May 2016. 124,901 exposed patients identified using clinical codes with newly diagnosed cancer were matched to 476,203 unexposed controls by age, gender, BMI, and general practice. The main outcome measure was the risk of developing UTC described by hazard ratios.

Results

There were 512 incident UTC events in the cancer group compared to 1787 in the unexposed controls. This translated to an adjusted hazard ratio of 1.26 (95% CI 1.14–1.39; p < 0.001). A sub-analysis assessing cancer-specific effects demonstrated increased risks for 10 out of 12 common cancers, most significantly in bladder, colorectal and prostate cancer.

Conclusion

This study demonstrated a 26% increased risk of UTC in cancer patients suggesting wider recognition of this risk amongst clinicians could improve diagnosis and prevention of UTC, as well as encourage further research exploring this association.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Raheem OA, Khandwala YS, Sur RL, Ghani KR, Denstedt JD (2017) Burden of urolithiasis: trends in prevalence, treatments, and costs. Eur Urol Focus 3:18–26CrossRefPubMed Raheem OA, Khandwala YS, Sur RL, Ghani KR, Denstedt JD (2017) Burden of urolithiasis: trends in prevalence, treatments, and costs. Eur Urol Focus 3:18–26CrossRefPubMed
2.
Zurück zum Zitat Scales CD, Smith AC, Hanley JM, Saigal CS, Urologic Diseases in America Project CS, Project UD in A (2012) Prevalence of kidney stones in the United States. Eur Urol 62:160–5CrossRefPubMedPubMedCentral Scales CD, Smith AC, Hanley JM, Saigal CS, Urologic Diseases in America Project CS, Project UD in A (2012) Prevalence of kidney stones in the United States. Eur Urol 62:160–5CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Kumar A, Mohanty NK, Jain M, Prakash S, Arora RP (2010) A prospective randomized comparison between early (< 48 hours of onset of colicky pain) versus delayed shockwave lithotripsy for symptomatic upper ureteral calculi: a single center experience. J Endourol 24:2059–2066CrossRefPubMed Kumar A, Mohanty NK, Jain M, Prakash S, Arora RP (2010) A prospective randomized comparison between early (< 48 hours of onset of colicky pain) versus delayed shockwave lithotripsy for symptomatic upper ureteral calculi: a single center experience. J Endourol 24:2059–2066CrossRefPubMed
6.
7.
Zurück zum Zitat Huncharek M, Vassilopoulou-Sellin R (1993) Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 72:956–957CrossRefPubMed Huncharek M, Vassilopoulou-Sellin R (1993) Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 72:956–957CrossRefPubMed
8.
Zurück zum Zitat Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, Ishii T, Dobashi H, Matsunaga T (2014) Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol 5:197CrossRefPubMedPubMedCentral Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, Ishii T, Dobashi H, Matsunaga T (2014) Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol 5:197CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Yuan C, Xu X-H, Wang X-L, Xu L, Chen Z, Li Y-Q (2016) Relationship between serum uric acid and metastatic and nonmetastatic rectal cancer patients with undergoing no chemotherapy. Medicine (Baltimore) 95:e5463CrossRef Yuan C, Xu X-H, Wang X-L, Xu L, Chen Z, Li Y-Q (2016) Relationship between serum uric acid and metastatic and nonmetastatic rectal cancer patients with undergoing no chemotherapy. Medicine (Baltimore) 95:e5463CrossRef
13.
Zurück zum Zitat Ferraro PM, Curhan GC (2017) Serum uric acid and risk of kidney stones. Am J Kidney Dis 70:158–159CrossRefPubMed Ferraro PM, Curhan GC (2017) Serum uric acid and risk of kidney stones. Am J Kidney Dis 70:158–159CrossRefPubMed
15.
Zurück zum Zitat Chow WH, Lindblad P, Gridley G, Nyrén O, McLaughlin JK, Linet MS, Pennello GA, Adami HO, Fraumeni JF (1997) Risk of urinary tract cancers following kidney or ureter stones. J Natl Cancer Inst 89:1453–1457CrossRefPubMed Chow WH, Lindblad P, Gridley G, Nyrén O, McLaughlin JK, Linet MS, Pennello GA, Adami HO, Fraumeni JF (1997) Risk of urinary tract cancers following kidney or ureter stones. J Natl Cancer Inst 89:1453–1457CrossRefPubMed
16.
Zurück zum Zitat Cheungpasitporn W, Thongprayoon C, O’Corragain OA, Edmonds PJ, Ungprasert P, Kittanamongkolchai W, Erickson SB (2015) The risk of kidney cancer in patients with kidney stones: a systematic review and meta-analysis. QJM 108:205–212CrossRefPubMed Cheungpasitporn W, Thongprayoon C, O’Corragain OA, Edmonds PJ, Ungprasert P, Kittanamongkolchai W, Erickson SB (2015) The risk of kidney cancer in patients with kidney stones: a systematic review and meta-analysis. QJM 108:205–212CrossRefPubMed
19.
Zurück zum Zitat Humphreys BD, Soiffer RJ, Magee CC (2005) Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol 16:151–161CrossRefPubMed Humphreys BD, Soiffer RJ, Magee CC (2005) Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol 16:151–161CrossRefPubMed
20.
Zurück zum Zitat Blak BT, Thompson M, Dattani H, Bourke A (2011) Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 19:251–255PubMed Blak BT, Thompson M, Dattani H, Bourke A (2011) Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 19:251–255PubMed
22.
Zurück zum Zitat Le Jeune I, Gribbin J, West J, Smith C, Cullinan P, Hubbard R (2007) The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med 101:2534–2540CrossRefPubMed Le Jeune I, Gribbin J, West J, Smith C, Cullinan P, Hubbard R (2007) The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med 101:2534–2540CrossRefPubMed
23.
Zurück zum Zitat Arana A, Wentworth CE, Fernández-Vidaurre C, Schlienger RG, Conde E, Arellano FM (2010) Incidence of cancer in the general population and in patients with or without atopic dermatitis in the UK. Br J Dermatol 163:1036–1043CrossRefPubMed Arana A, Wentworth CE, Fernández-Vidaurre C, Schlienger RG, Conde E, Arellano FM (2010) Incidence of cancer in the general population and in patients with or without atopic dermatitis in the UK. Br J Dermatol 163:1036–1043CrossRefPubMed
24.
Zurück zum Zitat Karim ME, Gustafson P, Petkau J, Tremlett H, Long-Term Benefits and Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study Group (2016) Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies. Am J Epidemiol 184:325–335CrossRefPubMedPubMedCentral Karim ME, Gustafson P, Petkau J, Tremlett H, Long-Term Benefits and Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study Group (2016) Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies. Am J Epidemiol 184:325–335CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Keane MG, Horsfall L, Rait G, Pereira SP (2014) A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer. BMJ Open 4:e005720CrossRefPubMedPubMedCentral Keane MG, Horsfall L, Rait G, Pereira SP (2014) A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer. BMJ Open 4:e005720CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat NHS Digital (2017) Quality and outcomes framework. NHS Digital, Leeds NHS Digital (2017) Quality and outcomes framework. NHS Digital, Leeds
29.
Zurück zum Zitat Denburg MR, Leonard MB, Haynes K, Tuchman S, Tasian G, Shults J, Copelovitch L (2014) Risk of fracture in urolithiasis: a population-based cohort study using the health improvement network. Clin J Am Soc Nephrol 9:2133–2140CrossRefPubMedPubMedCentral Denburg MR, Leonard MB, Haynes K, Tuchman S, Tasian G, Shults J, Copelovitch L (2014) Risk of fracture in urolithiasis: a population-based cohort study using the health improvement network. Clin J Am Soc Nephrol 9:2133–2140CrossRefPubMedPubMedCentral
30.
32.
Zurück zum Zitat Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR (2008) Management of complications of prostate cancer treatment. CA Cancer J Clin 58:196–213CrossRefPubMedPubMedCentral Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR (2008) Management of complications of prostate cancer treatment. CA Cancer J Clin 58:196–213CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström P-U, Choi W, Guo CC, Lotan Y, Kassouf W (2016) Bladder cancer. Lancet 388:2796–2810CrossRefPubMed Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström P-U, Choi W, Guo CC, Lotan Y, Kassouf W (2016) Bladder cancer. Lancet 388:2796–2810CrossRefPubMed
35.
Zurück zum Zitat Baker ML, Williams RN, Nightingale JMD (2011) Causes and management of a high-output stoma. Color Dis 13:191–197CrossRef Baker ML, Williams RN, Nightingale JMD (2011) Causes and management of a high-output stoma. Color Dis 13:191–197CrossRef
36.
37.
38.
Zurück zum Zitat Khan A (2018) Prevalence, pathophysiological mechanisms and factors affecting urolithiasis. Int Urol Nephrol 50:799–806CrossRefPubMed Khan A (2018) Prevalence, pathophysiological mechanisms and factors affecting urolithiasis. Int Urol Nephrol 50:799–806CrossRefPubMed
39.
Zurück zum Zitat Swann R, McPhail S, Witt J, Shand B, Abel GA, Hiom S, Rashbass J, Lyratzopoulos G, Rubin G (2018) Diagnosing cancer in primary care: results from the National Cancer Diagnosis Audit. Br J Gen Pract 68:e63–e72CrossRefPubMed Swann R, McPhail S, Witt J, Shand B, Abel GA, Hiom S, Rashbass J, Lyratzopoulos G, Rubin G (2018) Diagnosing cancer in primary care: results from the National Cancer Diagnosis Audit. Br J Gen Pract 68:e63–e72CrossRefPubMed
40.
Zurück zum Zitat Foster G, Stocks C, Borofsky MS (2006) Emergency department visits and hospital admissions for kidney stone disease, 2009: statistical brief #139. Agency for Healthcare Research and Quality (US) Foster G, Stocks C, Borofsky MS (2006) Emergency department visits and hospital admissions for kidney stone disease, 2009: statistical brief #139. Agency for Healthcare Research and Quality (US)
41.
Zurück zum Zitat Romero V, Akpinar H, Assimos DG (2010) Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol 12:e86–e96PubMedPubMedCentral Romero V, Akpinar H, Assimos DG (2010) Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol 12:e86–e96PubMedPubMedCentral
42.
Zurück zum Zitat Haschke M, Vitins T, Lude S, Todesco L, Novakova K, Herrmann R, Krahenbuhl S (2010) Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs. Nephrol Dial Transplant 25:426–433CrossRefPubMed Haschke M, Vitins T, Lude S, Todesco L, Novakova K, Herrmann R, Krahenbuhl S (2010) Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs. Nephrol Dial Transplant 25:426–433CrossRefPubMed
Metadaten
Titel
Cancer as a risk factor for urinary tract calculi: a retrospective cohort study using ‘The Health Improvement Network’
Cancer and urinary tract calculi
verfasst von
Ankush Mittal
Motaz Elmahdy Hassan
Joht Singh Chandan
Brian H. Willis
Krishnarajah Nirantharakumar
Kesvapilla Subramonian
Publikationsdatum
16.03.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Urolithiasis / Ausgabe 6/2019
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-019-01127-z

Weitere Artikel der Ausgabe 6/2019

Urolithiasis 6/2019 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.